Cargando…

Carbohydrate antigen 19-9 elevation without evidence of malignant or pancreatobiliary diseases

Although carbohydrate antigen 19-9 (CA 19-9) may be elevated in benign diseases, elevated CA 19-9 may cause a fear of cancer and unnecessary follow-up studies. Research on how to approach systematically in this case is very limited. The purpose of this study was to analyze the clinical features and...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Sunyoung, Park, Byung Kyu, Seo, Jeong Hun, Choi, Jinyoung, Choi, Jong Won, Lee, Chun Kyon, Chung, Jae Bock, Park, Yongjung, Kim, Dong Wook
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7264353/
https://www.ncbi.nlm.nih.gov/pubmed/32483216
http://dx.doi.org/10.1038/s41598-020-65720-8
_version_ 1783540956287467520
author Kim, Sunyoung
Park, Byung Kyu
Seo, Jeong Hun
Choi, Jinyoung
Choi, Jong Won
Lee, Chun Kyon
Chung, Jae Bock
Park, Yongjung
Kim, Dong Wook
author_facet Kim, Sunyoung
Park, Byung Kyu
Seo, Jeong Hun
Choi, Jinyoung
Choi, Jong Won
Lee, Chun Kyon
Chung, Jae Bock
Park, Yongjung
Kim, Dong Wook
author_sort Kim, Sunyoung
collection PubMed
description Although carbohydrate antigen 19-9 (CA 19-9) may be elevated in benign diseases, elevated CA 19-9 may cause a fear of cancer and unnecessary follow-up studies. Research on how to approach systematically in this case is very limited. The purpose of this study was to analyze the clinical features and the causes of CA 19-9 elevation without evidence of malignant or pancreatobiliary diseases. We retrospectively reviewed the medical records of patients who had CA 19-9 elevation (≥80 U/mL) and were found to be unrelated to cancer after follow-up. After exclusion, 192 patients were included in this study. The median level of CA 19-9 was 136.5 U/mL. The causes of CA 19-9 elevation were determined in 147 (76.6%) patients, and that was unknown in 45 (23.4%). The estimated causative diseases were hepatic diseases in 63 patients, pulmonary diseases in 32, gynecologic diseases in 38, endocrine diseases in 13, and spleen disease in 1. Of 45 patients with unknown cause, 35 had normalization of CA 19-9 and 10 had persistently elevated CA 19-9. In conclusion, CA 19-9 elevation without malignancies or pancreatobiliary diseases should be systematically evaluated and followed up. We suggest an algorithm to investigate the causes and follow up these patients.
format Online
Article
Text
id pubmed-7264353
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-72643532020-06-05 Carbohydrate antigen 19-9 elevation without evidence of malignant or pancreatobiliary diseases Kim, Sunyoung Park, Byung Kyu Seo, Jeong Hun Choi, Jinyoung Choi, Jong Won Lee, Chun Kyon Chung, Jae Bock Park, Yongjung Kim, Dong Wook Sci Rep Article Although carbohydrate antigen 19-9 (CA 19-9) may be elevated in benign diseases, elevated CA 19-9 may cause a fear of cancer and unnecessary follow-up studies. Research on how to approach systematically in this case is very limited. The purpose of this study was to analyze the clinical features and the causes of CA 19-9 elevation without evidence of malignant or pancreatobiliary diseases. We retrospectively reviewed the medical records of patients who had CA 19-9 elevation (≥80 U/mL) and were found to be unrelated to cancer after follow-up. After exclusion, 192 patients were included in this study. The median level of CA 19-9 was 136.5 U/mL. The causes of CA 19-9 elevation were determined in 147 (76.6%) patients, and that was unknown in 45 (23.4%). The estimated causative diseases were hepatic diseases in 63 patients, pulmonary diseases in 32, gynecologic diseases in 38, endocrine diseases in 13, and spleen disease in 1. Of 45 patients with unknown cause, 35 had normalization of CA 19-9 and 10 had persistently elevated CA 19-9. In conclusion, CA 19-9 elevation without malignancies or pancreatobiliary diseases should be systematically evaluated and followed up. We suggest an algorithm to investigate the causes and follow up these patients. Nature Publishing Group UK 2020-06-01 /pmc/articles/PMC7264353/ /pubmed/32483216 http://dx.doi.org/10.1038/s41598-020-65720-8 Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Kim, Sunyoung
Park, Byung Kyu
Seo, Jeong Hun
Choi, Jinyoung
Choi, Jong Won
Lee, Chun Kyon
Chung, Jae Bock
Park, Yongjung
Kim, Dong Wook
Carbohydrate antigen 19-9 elevation without evidence of malignant or pancreatobiliary diseases
title Carbohydrate antigen 19-9 elevation without evidence of malignant or pancreatobiliary diseases
title_full Carbohydrate antigen 19-9 elevation without evidence of malignant or pancreatobiliary diseases
title_fullStr Carbohydrate antigen 19-9 elevation without evidence of malignant or pancreatobiliary diseases
title_full_unstemmed Carbohydrate antigen 19-9 elevation without evidence of malignant or pancreatobiliary diseases
title_short Carbohydrate antigen 19-9 elevation without evidence of malignant or pancreatobiliary diseases
title_sort carbohydrate antigen 19-9 elevation without evidence of malignant or pancreatobiliary diseases
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7264353/
https://www.ncbi.nlm.nih.gov/pubmed/32483216
http://dx.doi.org/10.1038/s41598-020-65720-8
work_keys_str_mv AT kimsunyoung carbohydrateantigen199elevationwithoutevidenceofmalignantorpancreatobiliarydiseases
AT parkbyungkyu carbohydrateantigen199elevationwithoutevidenceofmalignantorpancreatobiliarydiseases
AT seojeonghun carbohydrateantigen199elevationwithoutevidenceofmalignantorpancreatobiliarydiseases
AT choijinyoung carbohydrateantigen199elevationwithoutevidenceofmalignantorpancreatobiliarydiseases
AT choijongwon carbohydrateantigen199elevationwithoutevidenceofmalignantorpancreatobiliarydiseases
AT leechunkyon carbohydrateantigen199elevationwithoutevidenceofmalignantorpancreatobiliarydiseases
AT chungjaebock carbohydrateantigen199elevationwithoutevidenceofmalignantorpancreatobiliarydiseases
AT parkyongjung carbohydrateantigen199elevationwithoutevidenceofmalignantorpancreatobiliarydiseases
AT kimdongwook carbohydrateantigen199elevationwithoutevidenceofmalignantorpancreatobiliarydiseases